Allink Biotherapeutics Completes $47M Extension Rounds of Series A

Allink Biotherapeutics, a clinical-stage biotech company, has completed a $47 million extension of its Series A funding round. The funding, led by Legend Capital and Meituan Long-Z Investment, will support the advancement of two antibody-drug conjugate (ADC) programs in Phase 1 trials and the development of ADC and multi-specific antibody platforms.